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Abstract: Human endogenous retroviruses (HERVs) represent approximately 8% of our 
genome. HERVs influence cellular gene expression and contribute to normal physiological 
processes such as cellular differentiation and morphogenesis. HERVs have also been 
associated with certain pathological conditions, including cancer and neurodegenerative 
diseases. As HTLV-1 causes adult T-cell leukemia and HTLV-1-associated myelopathy/tropical 
spastic paraparesis (HAM/TSP) and has been shown to modulate host gene expression 
mainly through the expression of the powerful Tax transactivator, herein we were 
interested in looking at the potential modulation capacity of HTLV-1 Tax on HERV 
expression. In order to evaluate the promoter activity of different HERV LTRs,   
pHERV-LTR-luc constructs were co-transfected in Jurkat T-cells with a Tax expression 
vector. Tax expression potently increased the LTR activity of HERV-W8 and HERV-H 
(MC16). In parallel, Jurkat cells were also stimulated with different T-cell-activating 




agents and HERV LTRs were observed to respond to different combination of Forskolin, 
bpV[pic] a protein tyrosine phosphatase inhibitor, and PMA. Transfection of expression 
vectors for different Tax mutants in Jurkat cells showed that several transcription factors 
including CREB appeared to be important for HERV-W8 LTR activation. Deletion 
mutants were derived from the HERV-W8 LTR and the region from −137 to −123 was 
found to be important for LTR response following Tax expression in Jurkat cells, while a 
different region was shown to be required in cells treated with activators. Our results thus 
demonstrated that HTLV-1 Tax activates several HERV LTRs. This raises the possibility 
that upregulated HERV expression could be involved in diseases associated with   
HTLV-1 infection. 
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1. Introduction 
An estimated 8% of our genome is derived from Human Endogenous Retrovirus (HERV), 
sequences which are resulting from integration events that took place millions of years ago. HERVs 
are known to have endogenized from ancestral exogenous retroviruses during primate evolution. 
HERVs are classified into 3 classes (class I, II, and III) based on their sequence similarities to different 
infectious retroviruses. Each class is divided in subgroups, based on the specificity of the tRNA 
primer-binding site (PBS) [1], i.e., HERV-W uses the tryptophan (W) tRNA as its primer whereas 
HERV-K uses the lysine (K) tRNA. While most HERVs are defective and unable to produce infectious 
particles, some of them have retained the capacity to encode viral proteins [2]. In addition, most 
HERVs have lost their entire coding sequences by homologous recombination between the two LTRs, 
leaving solitary LTRs [3]. These LTRs remain active in their promoter and can thereby modify the 
expression of adjacent cellular genes. 
HERV genes play an important role in many physiological events such as placental development 
[4,5], in which HERV-derived syncytin-1 and syncytin-2 genes seem to be the two major players by 
promoting the cellular fusion of trophoblasts [4,6]. On the other hand, HERVs have also been 
associated with several human autoimmune diseases and cancer. For instance, evidences suggest that 
syncytin-1 is involved in breast cancer [7,8] and multiple sclerosis [9]. In addition, a reduction in the 
expression of the capsid protein of HERV-W was observed in neurons and glial cells from brains of 
patients with schizophrenia, bipolar disorder and major depression [10], while HERV-W transcripts 
were more abundant in cerebrospinal fluid and plasma from patients with schizophrenia [11]. 
Human T-cell lymphotropic virus type-1 (HTLV-1) is the causative agents of adult T-cell leukemia 
(ATL) and has also been associated with a chronically progressive neuro-inflammatory disease known 
as HTLV-1 associated myelopathy or tropical spastic paraparesis (HAM/TSP). However, the majority 
of HTLV-1-infected patients remain asymptomatic throughout their lifetime. The HTLV-1 Tax protein 
is a powerful transactivator strongly suggested to be determinant in the development of ATL as well as 




transcription factors such as CREB, NF-B and SRF, which leads to upregulation or downregulation 
of a number of cellular genes [14–18]. 
Previous studies have shown that viruses such as HSV-1 and the Influenza virus could modulate 
HERV LTR activity [19–21]. Given that HERV overexpression has been associated with multiple 
sclerosis, a disease resembling HAM/TSP, we thereby tested whether the Tax protein could modulate 
HERV gene expression. Our results indeed confirm, that alike T cell activators, Tax significantly, yet 
selectively, induced LTR activity of several HERV family representatives. 
2. Results and Discussion  
2.1. Different HERV LTRs Are Activated upon T Cell Activation 
We first tested whether the activation of T lymphocytes could modulate the expression of HERVs. 
Different T-cell-activating agents known to activate many transcription factors in T-cells were thus 
first tested. Jurkat cells were transfected with luciferase reporter vectors harboring 5'LTR from 
different HERV families. LTRs from HERV-W4, HERV-W8, HERV W18, HERV-H (MC16), 
HERV-K (TD47) and HERV-E (E2) were thus tested individually for their responsiveness to T-cell 
activators. As shown in Figure 1A, HERV-W8 and HERV-H (MC16) LTRs were highly responsive to 
a combination of Forskolin and bpV[pic], a cAMP pathway activator and an inhibitor of protein 
tyrosine phosphatases, respectively and to the bpV[pic]/PMA combination. Both LTRs were also 
significantly responsive to the addition of bpV[pic] alone. While HERV-E and HERV-K representative 
LTRs were not activated by any tested agents, HERV-W4 and HERV-W8 presented a significant 
induction of LTR activity only in the presence of the Forskolin/bpV[pic] combination, although the 
response was more modest. To confirm these results, RNA from Jurkat cells was analyzed by RT-PCR 
for transcript levels of gag or pol genes from HERV-H, HERV-K, HERV-W and HERV-E families 
(Figure 1B). In bpV[pic]/Forskolin-stimulated cells, we confirmed that activation indeed led to an 
increase in HERV-W gag and HERV-H pol transcript levels when compared to untreated cells. A 
limited modulation of HERV-K gag and HERV-E pol expression was noted upon stimulation, again 
confirming the results obtained with the LTR constructs. The induction mediated by the 
bpV[pic]/PMA combination was also specific to HERV-H and HERV-W LTRs and was again less 
pronounced than the one observed with the Forskolin/bpV[pic] combination.  
We and others have previously indicated that the PTP inhibitor bpV[pic] in T-cells can activate a 
multitude of transcription factors, such as NF-B, NFAT, STAT, AP-1 and CREB [22–25]. Our results 
thereby first indicated that activation of T cells and activation of some of these transcription factors led 
to induction of HERV gene expression. Interestingly, we have previously demonstrated that 
Forskolin/bpV[pic] strongly induced the LTR of syncytin-1 (HERV-W) and syncytin-2 (HERV-FRD) 
genes in the choriocarcinoma BeWo cell line [4]. Other studies in T lymphocytes have indicated that 
HERV-H transcripts could be induced in T-cell leukemia cell lines by PHA [26] Our studies in the 
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reports had indeed indicated that HSV infection mediates LTR activation through Oct-1- and AP-1-
binding sites, respectively [19,20]. More specific studies focused on a HERV-W representative 
encoding for syncytin-1 have revealed that several transcription factors were acting on basal and 
cAMP-mediated LTR activation in trophoblast cells, such as GCMa, Sp1, GATA transcription factors 
and other potential transcription factors [5,32–34]. A potential NF-B-binding site has also been 
identified for its importance in TNF--mediated activation of syncytin-1 expression in astrocytes [35]. 
Our results suggest that different transcription factors act upon the induction of HERV-W8 LTR by  
T-cell activators and Tax. We are currently conducting experiments to more precisely identify these 
LTR regions. 
3. Experimental Section 
3.1. Plasmids 
pBL-based constructs containing different HERV LTRs (HERV-W4, HERV-W8, HERV-W18, 
HERV-E2, HERV-H (MC16), and HERV-K (TD47) inserted upstream of the firefly luciferase reporter 
have been previously described [36]. The Tax expression vector pHPr.1neoTax and the empty vector 
pHPr.1neo were generously provided by Dr. M. Nakamura (Tokyo Medical and Dental University, 
Tokyo, Japan) [37]. Vectors expressing wild-type and mutated Tax [38] were kindly provided by 
Dr.  J.M. Mesnard (Université Montpellier 1, Montpellier, France). The CREB dominant negative 
mutant KCREB and the control empty vector [39] were provided by Dr. R.H. Goodman (Vollum 
Institute for Advanced Biochemical, Research, Portland, OR, USA). The pRcActin-LacZ vector 
contains the -galactosidase gene under the control of the -actin. 
3.2. Generation of Deletions Mutants by Exonuclease III 
The pHERV-W8 LTR-Luc construct was first digested with BstX1 and BamHI and subsequently 
incubated in the presence of exonuclease III at 37 °C. At 15 s intervals, an aliquot was taken and added 
to a tube containing S1 nuclease. At the end of the time course, the S1 nuclease reaction was 
completed at 30 °C. Each samples were heat inactivated and after religation, transformed in DH5. 
Sequencing of plasmid DNA from resulting colonies was conducted for positioning the resulting 5' end 
of the LTR. Five deletion mutants were chosen for subsequent experiments. 
3.3. Transfection and Assay for Luciferase Activity  
Transfection of Jurkat cells was carried out by electroporation for 24 hours with a total of 15 µg of 
DNA (250 V and 950 µF) according to the Hughes and Pober’s protocol (Hughes and Pober, 1996). 
Transiently transfected cells were seeded at a density of 10
6  cells/well in 6-well plates and left 
unstimulated or treated for 8 h with PHA (3 µg/mL), PMA (20 ng/mL) (Sigma), ionomycin (1 µM) 
(Calbiochem), anti-CD3 antibody (clone OKT3) (3 µg/mL), anti-CD28 antibody (clone 9.3) (1 
µg/mL), Forskolin (100 µM) (BioMol, Plymouth Meeting, PA) and bpVpic (10 µM)   
in a final volume of 3 mL. Cells were then lysed in a 1× lysis buffer (25 mMTris phosphate, pH 7.8, 
2  mM DTT, 1% Triton X-100, 10% glycerol). Luciferase activity was determined as follows.   




plate and luciferase activity was quantified on a Dynex MLX microplate luminometer (MLX;   
Dynex Technologies, Chantilly, VA, USA) following a single injection of a luciferase buffer   
[137 mM NaCl, 20 mM tricine, 1.07 mM(MgCO3)4·Mg(OH)2·5H2O, 2.67 mM MgSO4, 0.1 mM 
EDTA (ethylenediaminetetraacetic acid), 220 μM coenzyme A, 4.7 μM D-luciferin potassium salt, 530 
μM ATP, 33.3 mM DTT]. β-galactosidase activity was measured using the Galacto-Light™ kit 
(Applied Biosystems, Bedford, MA, USA) according to manufacturer's instructions. Luciferase 
activity was calculated in terms of relative light units (RLU) and represents the mean ±SD of three 
transfected samples normalized for β-galactosidase activity. Fold inductions were calculated by 
dividing the values of activated samples by values of non-stimulated samples.  
3.4. Total RNA Extraction and Semi-Quantitative RT-PCR 
Total RNA was isolated from Jurkat cells using the Trizol reagent (Invitrogen Canada Inc). Prior to 
RT, total RNA was treated with TurboRNAse-Free DNAse (Ambion, Austin, TX, USA) for 5 min at 
70 °C. RNA (1 μg) was then incubated in the presence of oligo(dT) (25 ng/μL), 10 mM DTT, 100 mM 
dNTP (deoxynucleotide triphosphate), SuperScript reverse transcriptase (10 U) (Invitrogen Canada 
Inc.), and SUPERase-In (20 U) at 42 °C for 50 min. Aliquots from the RT reactions were then   
PCR-amplified in the presence of 1U Taq DNA polymerase (New England Biolabs, Pickering, 
Canada), 1× ThermoPol buffer, 100 μM dNTP, and 15 μM of each primer. Primers used for HERV-H 
pol cDNA amplification were 5'-CCTTTATTACCCAATCTGCTCCCGA(CT)AT-3'(forward) and  
5'-TTTAGTGGTGGACAGTCTCTTTTCCA(AG)TG-3' (reverse).  
For HERV-K gag cDNA amplification, the primers were  
5'-TCCCCTTGGAATACTCCTGTTTT(CT)GT-3' (forward) and  
5'-CATTCCTTGTGGTAAAACTTTCCA(CT)TG-3' (reverse).  
For HERV-W gag cDNA, the primers were 5'-GGCCAGGCATCAGCCCAAGACTTG-3' (forward) 
and 5'-CTTTAGGGCCTGGAAAGCCACT-3' (reverse), as for HERV-E pol cDNA amplification, the 
primers were 5'-CATCAACCTACTTGGGATTGTCA(AG)CA-3' (forward) and  
5'-CAATGACCTTTTTCTTTACAGTAGGC(AG)CA-3' (reverse).  
For RT-PCR analyses of β-actin mRNA, the primers 5'-CGTGACATTAAGGAGAAGCTG-3' 
(forward) and 5'-CTCAGGAGGAGCAATGATCTT-3'(reverse) were used. PCR conditions were as 
follows: a first step of denaturation at 95 °C for 3 min. followed by 35 cycles of denaturation (94 °C 
for 30 s), annealing (60 °C for 15 s) and elongation (72 °C for 12 s). 
3.5. Western Blot Analyses 
Western blot analyses from total protein isolated from transfected Jurkat cells were performed. 24 h 
post-transfection, cells were washed with PBS 1× and lysed with lysis buffer (50 mM  Tris-HCl,   
pH 7.4, 120 mM  NaCl, 5 mM  EDTA, 0.5% Nonidet P-40, 0.2 mM  Na3VO4, 1 mM  dithiothreitol,   
1 mM phenylmethylsulfonyl fluoride) in the presence of protease inhibitors (Complete, Roche Applied 
Science), and incubated on ice for 30 minutes. Cell debris were pelleted by centrifugation for 10 min at 
high speed. Protein concentrations were quantified with the bicinchoninic acid (BCA) protein assay 
(Thermo Fisher Scientific Inc., Rochester, NY, USA). Extracts were migrated on a 12% sodium 




fluoride (PVDF) membrane (Millipore). Membrane was blocked with 5% Bovine Serum Albumin 
(BSA) and incubated with anti-Tax antibody (dilution, 1/100) (or a polyclonal anti-glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) antibody (1/5000; Santa Cruz, CA, USA). Membranes were 
further incubated with a horseradish peroxidase-coupled anti-mouse antibody (1/10,000) (Amersham 
Biosciences, Buckinghamshire, UK), and signals were detected using the BM chemiluminescence 
blotting substrate (Roche Diagnostics). Membranes were subsequently exposed on an ECL high 
performance chemiluminescence film (Amersham Biosciences). Antibodies from the HTLV-I Tax 
hybridoma 168A51-42 (Tab176) was obtained from Dr. J.M. Mesnard [40]. 
3.6. Statistical Analyses 
All experiments were performed in triplicates. Results are expressed as the mean+SEM and 
statistically analyzed using a 2-tailed Student t test for 2-group comparisons. 
4. Conclusions 
We herein have demonstrated that LTRs from different HERV families can both be activated by the 
combination of T-cell activation agent bpV[pic]/Forskolin and bpV[pic]/PMA and by the Tax 
transactivator. Furthermore, we identified a Tax-responsive region different from the region responsive 
to T-cell activators suggesting the implication of different transcription factors. Indeed the use of the 
various Tax mutants reveals that each of them affects this LTR activation at different degrees. Through 
the CREB dominant negative mutant, our results argue that members of the CREB/ATF family are 
playing a role in the upregulation of the LTR activity. The HTLV-1 Tax protein is a powerful 
transactivator, capable of inducing many cellular genes with its activation domains. It is thereby not 
surprising that it also acts on the HERV-W LTRs, which are known to be upregulated by inducing 
agents such as Forskolin and bpV[pic] in human trophoblasts and by HSV-1 and Influenza virus 
infection [4,20,21]. We conclude that Tax can modulate these LTRs in Jurkat cells by activating CREB 
and possibly NF-қB, which can positively regulate the transcription of the HERVs genes or other 
cellular genes in proximity. Transcription factors mediating the upregulation of HERV LTRs by both 
Tax and T-cell activators are likely different and we are currently working on their identification. 
Since our results indicate that Tax can modulate the expression of HERVs, a link between   
HTLV-1-associated diseases and HERV dysregulation is an interesting speculation. Indeed, 
upregulation of HERV gene expression has been associated with various inflammatory and 
autoimmune diseases such as multiple sclerosis and arthritis [9,41]. Interestingly, HTLV-1-associated 
diseases HAM/TSP and HTLV-1-associated arthropathy have been shown to be very similar to these 
latter diseases. In addition, activation of HERV LTR nearby proto-oncogenes may constitute a 
mechanism by which Tax could promote cell transformation via HERV sequences. Alternatively, 
induced expression of near full-length HERV proviral DNA could generate potential substrates for 
reverse transcriptase activity. Newly synthesized proviruses could then reintegrate the host genome in 
infected cells and contribute to genomic instability.  
More advanced studies are needed to clearly determine if HERV expression is increased in 
HTLV-1-infected patients and modulated during the course of HTLV-1-induced pathologies. 




of HTLV-1. Clearly, other viral proteins such as HBZ could impact on the extent of Tax-mediated 
HERV LTR activation or could affect HERV LTR activation. These experiments, as well as the 
analysis of HERV expression in HTLV-I-infected cells are currently ongoing. These studies will 
indicate whether HERVs could become possible new disease markers in HTLV-1-infected patients. 
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